Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | ZBIO | FORTY |
|---|---|---|
| Price | $27.83 | $118.15 |
| Change today | ▼ 1.64% | ▲ 4.09% |
| Market cap | $1.81B | $1.81B |
| Return, 3 months | +0.5% | +6.0% |
| Return, year to date | -23.4% | -21.2% |
| Return, 1 year | +20.8% | -7.0% |
| P/E (TTM) | -2.9 | 3.0 |
| P/B | 7.3 | 1.5 |
| P/E percentile vs own 5y | – | 5th |
| Dividend yield | – | 0.88% |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | – |
| Analyst target vs. price | +61.0% | – |
| Analyst buy share | 80% | – |
| RSI (14) | 40 | 54 |
| 30-day volatility | 54.5% | 29.0% |
| Max drawdown, 1 year | -64.8% | -42.0% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
